RITONAVIR

Post-LOESM

ritonavir

Hetero

ANDAORALTABLET

Approved

Sep 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

RITONAVIR (ritonavir) by Hetero is hiv protease inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection ( ). First approved in 2018.

Drug data last refreshed 15h ago

$0.0BPart D

Mechanism of Action

HIV Protease Inhibitors

Pharmacologic Class:

Cytochrome P450 3A Inhibitor

Indications (1)

combination with other antiretroviral agents for the treatment of HIV-1 infection ( )

Clinical Trials (20)

NCT00084058Phase 1/2Completed

Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV

26 enrolled

HIV Infections

NCT00000888Phase 1Completed

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

14 enrolled

HIV InfectionsPregnancy

NCT00000898N/ACompleted

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

18 enrolled

HIV Infections

NCT00038480Phase 1Completed

Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

31 enrolled

HIV Infections

NCT00028366N/ACompleted

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

56 enrolled

HIV Infections

Worked on RITONAVIR at Hetero? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.